Get the Stockscreener App
0.3931
5.98%
-0.025
After Hours:
.38
-0.0131
-3.33%
Tnf Pharmaceuticals Inc stock is traded at $0.3931, with a volume of 969.97K.
It is down -5.98% in the last 24 hours and down -46.00% over the past month.
TNF Pharmaceuticals Inc is a clinical-stage pharmaceutical company committed to extending a healthy lifespan. The company is developing and commercializing two therapeutic platforms. MyMD-1 is a small molecule that regulates the immunometabolic system to treat autoimmune diseases, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. It is being developed to treat age-related illnesses such as frailty and sarcopenia. Supera-CBD is a synthetic derivative of CBD being developed to treat various conditions, including epilepsy, pain, and anxiety/depression, through its effects on the CB2 receptor, opioid receptors, and monoamine oxidase enzyme type B.
See More
Previous Close:
$0.4181
Open:
$0.41
24h Volume:
969.97K
Relative Volume:
2.09
Market Cap:
$1.10M
Revenue:
-
Net Income/Loss:
$-23.66M
P/E Ratio:
-0.0284
EPS:
-13.84
Net Cash Flow:
$-10.14M
1W Performance:
-10.56%
1M Performance:
-46.00%
6M Performance:
-76.37%
1Y Performance:
+0.00%
1-Day Range:
$0.3755
$0.4253
1-Week Range:
$0.3755
$0.53
52-Week Range:
$0.3755
$2.16
Tnf Pharmaceuticals Inc Stock (TNFA) Company Profile
Name
Tnf Pharmaceuticals Inc
Sector
Industry
Phone
856-848-8698
Address
855 N. WOLFE STREET, BALTIMORE
Compare TNFA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TNFA
Tnf Pharmaceuticals Inc
|
0.3931 | 1.10M | 0 | -23.66M | -10.14M | -13.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.31 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.87 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
622.61 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
111.56 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Tnf Pharmaceuticals Inc Stock (TNFA) Latest News
RILY’s current quarter earnings: What analysts forecast? - US Post News
LGVN To Complete ELPIS II Enrollment By Q2, Time To Keep An Eye On NXGL, What's The Buzz At ACON? - RTTNews
Are T1 Energy Inc (FREY) shares a good deal now? - US Post News
TNF Pharmaceuticals Initiates Phase 2b Clinical Trial of First Oral TNF-Alpha Inhibitor - BioSpace
Can This First-Ever Oral TNF Inhibitor Disrupt a $40 Billion Market? Phase 2b Trial Begins - StockTitan
TNFA stock touches 52-week low at $0.43 amid market challenges - Investing.com Australia
Sarcopenia Market Share Projected to Climb to USD 4.23 Billion by 2030 - Industry Today
TNFA stock touches 52-week low at $0.48 amid market challenges - MSN
TNFA stock touches 52-week low at $0.48 amid market challenges By Investing.com - Investing.com South Africa
Teva- Pharmaceutical Industries Ltd. ADR’s: Contrasting Stock Performances in a Volatile Market - The InvestChronicle
FHN’s Stock Market Expedition: Traversing Gains and Losses in 2023 - The InvestChronicle
Bio-Thera Solutions Announces Exclusive Commercialization and License Agreement with Intas Pharmaceuticals for BAT2506, a Proposed Biosimilar Referencing Simponi® (golimumab), in the United States of America - BioSpace
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Post-Trade Analysis: Avinger Inc (AVGR) Slides -30.15, Closing at 0.39 - The Dwinnex
Daily Market Movement: Lottery.com Inc (LTRY) Sees a 187.81 Increase, Closing at 1.41 - The Dwinnex
In the Green: TNF Pharmaceuticals Inc (TNFA) Closes at 0.60, Up/Down 6.96 from Previous Day - The Dwinnex
TNFA stock touches 52-week low at $1.02 amid market challenges - MSN
TNFA stock touches 52-week low at $1.02 amid market challenges By Investing.com - Investing.com South Africa
TNF Pharmaceuticals to study TNF-alpha in patients taking GLP-1s - TipRanks
TNF Pharmaceuticals Launches Study Series Aimed at Preserving Lean Muscle Mass During GLP-1 Weight Loss Treatment - Marketscreener.com
Revolutionary Drug Could Solve the Hidden Problem with Ozempic and Wegovy Weight Loss - StockTitan
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
InMed's Alzheimer's Drug Shows Breakthrough Results in Reducing Brain Inflammation - StockTitan
Coeptis Therapeutics (Nasdaq: COEP) Emerges as a Biopharma Innovator Leveraging AI-Driven Marketing - The Globe and Mail
TNF Pharmaceuticals to expand clinical trials for isomyosamine - Investing.com
TNF Pharmaceuticals Announces Positive Clinical Data Supporting Clinical Trial Expansion - Business Wire
Shattuck Labs CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
TNF Pharmaceuticals Announces Trial to Explore Effects of Lead Candidate in Sarcopenia/Frailty Induced by GLP-1 Weight Loss Drugs - Business Wire
PharmaCyte Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2024 - Marketscreener.com
Inflammatory Bowel Disease Treatment Market Report 2024, Share And Growth - WhaTech
TNF Alpha Inhibitors Market Overview 2024-2033 – Share, Trends, Demand, Outlook - WhaTech
Premarket Action Is Heating Up For This Biotech - MSN
PHLX Japanese Yen (XDN) QuotePress Release - The Globe and Mail
TSX Consumer Staples Capped Index (TTCS) QuotePress Release - The Globe and Mail
TSX Venture Composite Index (JX) QuotePress Release - The Globe and Mail
Tnf Pharmaceuticals Inc (TNFA-Q) QuotePress Release - The Globe and Mail
TNF Pharmaceuticals Presents Statistically Significant Phase 2a Trial Results for Novel Sarcopenia/Frailty Treatment at Prestigious International Conference - BioSpace
TNF Pharmaceuticals Reports Breakthrough Phase 2a Results for Novel Sarcopenia Treatment - StockTitan
Tumor necrosis factor (TNF)-alpha Inhibitor Market Will Witness Growth with Emerging Therapies by 2034 | - EIN News
TNF Alpha Inhibitors Global Market Demand Analysis, - openPR
Tumor Necrosis Factor Inhibitor Drugs Market Report 2024, Trends and Forecast In The New Analysis By Leadin... - WhaTech
TNFA stock touches 52-week low at $1.12 amid market challenges - Investing.com Nigeria
TNF Pharmaceuticals announces board re-elections and incentive plan expansion - Investing.com India
TNF Pharmaceuticals Announces New Board and Shareholder Votes - TipRanks
FDA Roundup: Rheumatology Drug Alerts 2024 - Rheumatology Advisor
TNF Pharmaceuticals Inc (TNFA) Quarterly 10-Q Report - Quartzy
TNFA Stock Plummets to 52-Week Low at $1.15 Amid Market Struggles - Investing.com UK
Some Major Key Players In The Psoriasis Biosimilars Market: - InsightAce Analytic
Adalimumab Market 2024: Industry Growth and Future Scope - openPR
Tnf Pharmaceuticals Inc Stock (TNFA) Financials Data
Revenue
Net Income
Cash Flow
EPS
6.45%
1.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):